India's National IPR policy: what's cooking?
This article was originally published in Scrip
India appears to be on course to releasing its National Intellectual Property Rights (IPR) policy but some industry experts say they are concerned that, despite seeming assurances, concessions around "patent linkage" and "data exclusivity" may find their way into the final framework.
You may also be interested in...
India new National Intellectual Property Rights (IPR) policy appears to have steered clear of a host of prickly issues pertaining to the pharmaceutical industry for now while standing firm on the need for "strong measures" against attempts to treat generic drugs as "spurious or counterfeit".
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.